b
r
c
haploident
hematopoiet
stem
cell
transplant
haplohsct
condit
regimen
use
posttranspl
cyclophosphamid
ptci
peripher
blood
stem
cell
pbsc
graft
limit
compar
higher
rate
acut
chronic
graftversushost
diseas
gvhd
antithymocyt
globulin
atg
may
mitig
risk
evalu
haplohsct
reducedintens
condit
ric
atg
ptci
cyclosporin
prevent
reject
gvhd
fifti
adult
underw
haplohsct
august
februari
ric
includ
fludarabin
mgm
day
day
busulfan
mgm
day
day
total
bodi
irradi
cgi
day
unmanipul
pbsc
infus
day
gvhd
prophylaxi
includ
atg
mgkg
day
ptci
mgkgday
day
cyclosporin
day
median
age
year
rang
year
patient
first
complet
remiss
second
complet
remiss
activ
diseas
median
time
neutrophil
engraft
day
rang
day
day
cumul
incid
acut
gvhd
grade
grade
iii
iv
respect
mild
chronic
gvhd
seen
cytomegaloviru
cmv
reactiv
occur
case
cmv
diseas
occur
case
epsteinbarr
viru
ebv
reactiv
occur
patient
incid
histolog
confirm
posttransplant
lymphoprolif
disord
ptld
four
patient
receiv
rituximab
cmv
ebv
ptldrelat
death
sixmonth
overal
surviv
os
cumul
incid
relaps
cir
nonrelaps
mortal
nrm
respect
respect
infect
common
caus
death
unmanipul
haploident
pbsc
transplant
follow
ric
atg
ptci
cyclosporin
gvhd
prevent
strategi
result
low
rate
acut
chronic
gvhd
allogen
hematopoiet
stem
cell
transplant
hsct
potenti
cur
therapi
patient
highrisk
advanc
hematolog
disord
hlamatch
sibl
donor
consid
first
choic
approxim
patient
suitabl
match
sibl
donor
msd
avail
transplant
altern
match
unrel
donor
mud
identifi
patient
donor
search
procur
process
requir
median
month
patient
suitabl
msd
mud
altern
stem
cell
sourc
includ
unrel
singl
doubl
umbil
cord
blood
transplant
hlamismatch
unrel
donor
mmud
hla
haploident
famili
member
despit
expans
mud
registri
cord
blood
bank
donor
avail
often
uncertain
particularli
underrepres
ethnic
minor
may
subject
prolong
unproduct
registri
search
use
haploident
donor
reduc
uncertainti
larg
degre
almost
patient
immedi
avail
relat
donor
share
singl
hla
haplotyp
facilit
reduc
time
transplant
also
provid
reliabl
sourc
donor
remain
consider
variat
center
condit
regimen
graft
sourc
choic
graftversushost
diseas
gvhd
prophylaxi
achiev
lower
nonrelaps
mortal
nrm
optimum
longterm
outcom
haploident
hsct
haplohsct
combin
nonmyeloabl
condit
regimen
antithymocyt
globulin
atg
posttranspl
highdos
cyclophosphamid
ptci
describ
set
haplohsct
sickl
cell
diseas
institut
establish
reducedintens
condit
ric
regimen
consist
fludarabin
flu
reduceddos
busulfan
bu
total
bodi
irradi
tbi
total
dose
cgi
combin
atg
follow
ptci
cyclosporin
prevent
graft
reject
gvhd
haplohsct
recipi
previous
report
use
protocol
mud
transplant
wherein
lower
rate
sever
acut
gvhd
demonstr
compar
regimen
present
studi
report
use
protocol
consecut
patient
underw
haplohsct
center
august
februari
adult
patient
hematolog
malign
underw
haplohsct
princess
margaret
cancer
centr
toronto
canada
patient
year
old
upper
age
limit
karnofski
perform
score
kp
activ
untreat
infect
human
immunodefici
viru
seroposit
criteria
pretranspl
organ
function
includ
left
ventricular
eject
fraction
without
signific
preexist
cardiac
diseas
pulmonari
function
test
demonstr
forc
expiratori
volum
predict
diffus
capac
carbon
monoxid
normalst
kidney
function
biochemistri
liver
function
test
show
total
bilirubin
time
normal
transaminas
time
upper
limit
normal
inform
consent
obtain
patient
use
protocol
approv
institut
board
ethic
patient
posit
donor
specif
antibodi
exclud
highresolut
molecular
type
hla
class
b
c
class
ii
dr
dq
perform
recipi
donor
patient
refer
allogen
blood
marrow
transplant
program
haploident
relat
donor
select
case
msd
mud
could
identifi
peripher
blood
stem
cell
pbsc
collect
granulocyt
colonystimul
factor
gcsf
mobil
minimum
dose
cellskg
recipi
bodi
weight
request
case
cell
enumer
routin
perform
institut
unmanipul
stem
cell
use
case
donor
provid
inform
consent
patient
receiv
condit
therapi
fludarabin
mgm
day
v
day
busulfan
mgm
day
iv
day
cgi
tbi
day
rabbit
atg
thymoglobulin
genzymesanofi
lyon
franc
administ
dose
mgkg
day
mgkg
day
mgkg
day
total
mgkg
pbsc
graft
infus
day
patient
receiv
ptci
cyclophosphamid
mgkgday
iv
day
first
dose
start
hour
start
allograft
infus
four
dose
mesna
administ
day
total
daili
dose
cyclophosphamid
dose
cyclosporin
initi
dose
mgkg
iv
day
adjust
achiev
therapeut
level
mgl
figur
patient
receiv
daili
filgrastim
mg
subcutan
start
day
neutrophil
l
ursodeoxychol
acid
mg
oral
twice
daili
meal
start
first
day
condit
use
prevent
sinusoid
obstruct
syndrom
so
patient
prophylact
antimicrobi
therapi
includ
posaconazol
mg
daili
acyclovir
mg
twice
daili
ciprofloxacin
mg
twice
daili
inhal
pentamidin
mg
monthli
postengraft
cytomegaloviru
cmv
titer
monitor
twice
per
week
epsteinbarr
viru
ebv
monitor
weekli
cyclosporin
taper
start
around
day
patient
without
gvhd
schemat
condit
protocol
posttranspl
immunosuppress
regimen
shown
figur
neutrophil
engraft
defin
first
consecut
day
absolut
neutrophil
count
l
platelet
recoveri
defin
sustain
transfusionindepend
platelet
count
l
first
day
without
transfus
time
day
donor
total
chimer
assess
whole
blood
pcr
variabl
number
tandem
repeat
polymorph
day
patient
patient
underw
bone
marrow
examin
day
marrow
cellular
diseas
monitor
clinic
featur
posttranspl
outcom
side
effect
collect
retrospect
chart
review
last
followup
updat
februari
studi
conduct
accord
declar
helsinki
review
approv
ethic
committe
princess
margaret
cancer
centr
toronto
canada
patient
diseas
characterist
report
use
descript
statist
count
percentag
time
event
calcul
date
transplant
date
event
last
date
patient
known
aliv
main
outcom
variabl
interest
includ
overal
surviv
os
relapsefre
surviv
rf
nonrelaps
mortal
nrm
kaplanmei
method
use
estim
os
rf
cumul
incid
acut
chronic
gvhd
calcul
account
death
relaps
compet
risk
incid
rate
acut
gvhd
estim
day
chronic
gvhd
day
nrm
estim
use
cumul
incid
method
account
relaps
compet
risk
fineandgray
analysi
surviv
rate
calcul
month
year
haplohsct
analys
perform
use
spss
version
window
spss
inc
chicago
il
ezr
tabl
show
baselin
patient
characterist
tabl
show
donor
characterist
graft
paramet
gvhd
characterist
median
followup
survivor
day
rang
day
month
rang
month
nearli
donorrecipi
pair
mismatch
hla
loci
sixteen
patient
donor
cmv
mismatch
cryopreserv
graft
use
major
patient
receiv
fresh
product
hematopoiet
cell
transplant
comorbid
index
score
almost
case
median
time
neutrophil
engraft
day
rang
day
median
time
platelet
engraft
day
rang
day
engraft
syndrom
character
fever
fluid
retentionweight
gain
hypotens
hypoxemia
absenc
document
infect
tempor
correl
count
recoveri
occur
patient
case
success
treat
steroid
ninetyfour
percent
patient
achiev
donor
chimer
day
four
patient
fail
engraft
day
one
patient
develop
secondari
graft
failur
month
posttranspl
includ
patient
primari
myelofibrosi
myelodysplast
syndrom
acut
myelogen
leukemia
median
kg
recipi
bodi
weight
rang
kg
recipi
bodi
weight
infus
donorspecif
antibodi
document
patient
develop
cmv
reactiv
patient
secondari
graft
failur
biopsyproven
cmv
coliti
ebv
reactiv
document
case
develop
asymptomat
bk
viruria
median
length
hospit
day
rang
day
posttranspl
clinic
cours
organ
toxic
infect
summar
supplementari
tabl
three
case
develop
lowgrad
cytokin
releas
syndrom
follow
stem
cell
infus
occur
day
case
resolv
cyclophosphamid
administr
case
day
mild
mucos
seen
patient
patient
develop
grade
mucos
requir
shortterm
total
parenter
nutrit
mildtomoder
so
document
patient
grade
so
case
case
resolv
fluid
restrict
diuret
ten
patient
develop
featur
fluid
overload
patient
develop
cardiogen
pulmonari
edema
secondari
fluid
retent
hypoalbuminemia
first
day
posttranspl
cours
case
respond
aggress
diuresi
fluid
optim
patient
need
intens
care
support
ischem
event
occur
three
patient
develop
pericardi
complic
case
pericard
myopericard
followup
effus
mild
resolv
spontan
show
featur
cardiac
tamponad
diagnost
therapeut
pericardiocentesi
perform
one
patient
demonstr
appreci
declin
left
ventricular
eject
fraction
followup
echocardiographi
remain
asymptomat
one
patient
histori
anthracyclineassoci
cardiomyopathi
induct
chemotherapi
sustain
fatal
ventricular
arrhythmia
undergo
treatment
cmv
reactiv
gvhd
transient
elev
renal
paramet
without
oliguria
seen
patient
creatinin
return
baselin
case
conserv
manag
neutropen
fever
occur
patient
posit
blood
cultur
nineteen
case
proven
invas
fungal
infect
encount
hospit
transplant
laboratori
evid
cmv
reactiv
peripher
blood
pcr
observ
patient
median
time
reactiv
day
rang
day
posttranspl
cmv
also
identifi
bronchoalveolar
lavag
specimen
case
intestin
biopsi
case
patient
receiv
intraven
ganciclovir
valgancyclovir
viremia
clearanc
two
patient
requir
foscarnet
therapi
due
persist
cmv
viremia
despit
appropri
dose
ganciclovir
twentyseven
patient
develop
ebv
reactiv
transplant
median
time
day
rang
day
four
patient
develop
biopsi
proven
posttranspl
lymphoprolif
diseas
ptld
ptld
manag
taper
immunosuppress
weekli
rituximab
maximum
dose
rate
acut
chronic
gvhd
respect
acut
gvhd
grade
accord
keyston
criteria
chronic
gvhd
grade
accord
nation
institut
health
chronic
graftversushost
diseas
consensu
acut
gvhd
grade
identifi
patient
howev
grade
iii
iv
acut
gvhd
occur
case
cumul
incid
acut
gvhd
grade
grade
ii
iv
grade
iii
iv
day
respect
tabl
skin
commonli
affect
site
follow
liver
gut
firstlin
therapi
clinic
signific
acut
gvhd
consist
topic
system
steroid
base
site
sever
cumul
incid
chronic
gvhd
month
system
immunosuppress
requir
patient
chronic
gvhd
patient
develop
moder
sever
chronic
gvhd
tabl
nineteen
patient
die
followup
tabl
list
caus
death
among
transplant
patient
five
patient
relaps
followup
period
median
time
relaps
month
rang
month
sixmonth
os
rf
cir
nrm
respect
signific
differ
found
os
p
progressionfre
surviv
p
patient
versu
versu
activ
diseas
oneyear
os
rf
cir
nrm
respect
tabl
caus
death
relaps
case
graft
failur
patient
infect
patient
multiorgan
failur
case
acut
gvhd
case
cardiac
arrhythmia
case
figur
haplohsct
initi
describ
late
histor
associ
high
rate
graft
reject
sever
acut
gvhd
wors
outcom
compar
msd
transplant
import
mileston
haplohsct
use
graft
combin
posttransplant
highdos
cyclophosphamid
set
haplohsct
ptci
decreas
risk
gvhd
graft
reject
target
induc
cell
apoptosi
alloreact
cell
rapidli
prolifer
earli
transplant
spare
regulatori
cell
preserv
nondivid
hematopoiet
stem
progenitor
cell
ptci
may
associ
high
rate
sever
acut
gvhd
use
alon
patient
receiv
singleag
ptci
succumb
fatal
steroidrefractori
gvhd
singlecent
report
therefor
posttranspl
immunosuppress
commonli
includ
addit
agent
calcineurin
inhibitor
sirolimu
andor
mycophenol
mofetil
haplohsct
use
unmanipul
pbsc
graft
ptci
calcineurin
inhibitor
mycophenol
mofetil
gvhd
prophylaxi
associ
increas
rate
acut
chronic
gvhd
shown
commensur
outcom
accept
nrm
compar
donor
sourc
atg
also
extens
studi
method
prevent
graft
reject
acut
gvhd
chronic
gvhd
msd
mud
transplant
howev
effect
modul
sever
acut
chronic
gvhd
offset
higher
rate
infecti
complic
includ
cmv
ebv
reactiv
ptci
induc
select
destruct
prolifer
cell
effect
invalu
haplohsct
intens
cell
prolifer
due
major
hla
mismatch
donor
memori
cell
rel
protect
ptci
provid
donor
immun
addit
immun
reconstitut
posttranspl
reducedintens
condit
fludarabin
reduceddos
busulfan
tbi
cgi
lowtox
regimen
induc
suffici
immunosuppress
permit
donor
hematopoiet
cell
consist
engraft
despit
hlahaplotyp
barrier
feasibl
ric
haplohsct
adult
patient
hematolog
malign
well
describ
combin
fludarabin
busulfan
ptci
may
potenti
antineoplast
activ
condit
regimen
may
lead
result
diseas
reduct
data
haplohsct
use
ric
pbsc
stem
cell
sourc
limit
addit
center
use
pbsc
haploident
transplant
shown
rate
extens
chronic
gvhd
high
combin
atg
low
dose
ptci
found
increas
regulatori
cell
reconstitut
anim
model
lead
lower
rate
acut
gvhd
murin
experi
experi
combin
mud
transplant
led
use
haplohct
set
also
encount
high
incid
sever
acut
chronic
gvhd
ric
msd
mud
transplant
led
concert
effort
design
condit
regimen
would
reduc
acut
chronic
gvhd
ric
lowdos
busulfan
fludarabin
atg
gvhd
prophylaxi
show
outcom
compar
mud
lower
rate
cgvhd
inclus
atg
condit
regimen
result
faster
achiev
donor
chimer
especi
use
altern
donor
howev
use
atg
also
associ
delay
immun
reconstitut
increas
infect
complic
particularli
viral
reactiv
cmv
ebv
due
higher
degre
immunosuppress
haplohsct
recipi
increas
risk
infecti
complic
particularli
viral
infect
includ
cmv
reactiv
high
incid
cmv
reactiv
note
studi
howev
cmvrelat
mortal
low
haplohsct
recipi
lower
incid
infect
haplohsct
patient
improv
immun
reconstitut
incid
cmv
reactiv
report
best
approach
prevent
cmv
reactiv
set
haplohsct
well
establish
use
novel
agent
letermovir
prophylaxi
may
potenti
use
avenu
research
ebvrel
ptld
allogen
hsct
associ
mortal
rate
high
base
european
data
incid
ptld
allogen
hsct
vari
mud
mismatch
relat
donor
includ
haploident
mismatch
relat
donor
context
atgbas
condit
incid
ptld
report
risk
develop
ebvptld
predominantli
relat
degre
cell
deplet
impair
ebvinfect
b
cell
held
check
cytotox
cell
lymphocyt
loss
mechan
lead
uncontrol
b
cell
prolifer
develop
ptld
although
incid
ebv
reactiv
ptld
patient
high
patient
respond
well
rituximab
monotherapi
ptldrelat
death
occur
observ
high
rate
ebv
reactiv
ptld
may
attribut
cell
impair
donor
recipi
secondari
hla
mismatch
use
dual
cell
deplet
ptci
atg
high
rate
cmv
reactiv
patient
monitor
close
weekli
pcrbase
test
ebv
may
led
higher
rate
detect
ebv
reactiv
ebv
seromismatch
describ
risk
factor
ptld
develop
select
ebvmatch
donor
may
affect
rate
reactiv
manner
similar
cmv
clear
guidelin
monitor
preemptiv
treatment
ebv
reactiv
ptld
haplohsct
studi
major
limit
short
durat
followup
focu
report
demonstr
applic
novel
condit
regimen
broad
select
patient
longer
followup
would
certainli
inform
outcom
chronic
gvhd
longerterm
complic
lower
incid
acut
gvhd
grade
ii
iv
encourag
incid
nrm
consider
concern
attribut
infect
complic
particularli
viral
infect
implement
reduct
atg
dose
attempt
mitig
infect
risk
final
proport
older
year
age
patient
may
explain
lower
toler
infecti
posttranspl
complic
futur
modif
protocol
may
also
includ
aggress
antivir
prophylaxi
therapi
summar
experi
indic
haplohsct
ric
lowdos
busulfan
fludarabin
tbi
cgi
combin
atg
ptci
cyclosporin
feasibl
effect
transplant
regimen
approach
produc
consist
donor
cell
engraft
low
rate
acut
gvhd
howev
temper
high
rate
viral
reactiv
consequ
nrm
haplohsct
may
use
suitabl
hlamatch
donor
avail
allogen
hsct
need
urgent
prospect
studi
need
compar
outcom
differ
condit
regimen
haplohsct
outcom
allogen
hsct
use
altern
graft
sourc
financi
disclosur
author
noth
disclos
conflict
interest
statement
conflict
interest
report
authorship
statement
al
qs
collect
analyz
data
contribut
equal
write
manuscript
wl
st
jl
fm
rk
dk
hm
av
provid
valuabl
input
studi
design
analysi
interpret
review
manuscript
supplementari
data
relat
articl
found
onlin
